Prasugrel 13C6

[13C6]-Prasugrel is a labeled version of the antiplatelet drug prasugrel. Prasugrel is a thienopyridine derivative that is used in the treatment of acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). It works by inhibiting the activation of platelets, thereby preventing the formation of blood clots that can lead to heart attacks and strokes. The labeled version, [13C6]-Prasugrel, is used in pharmacokinetic and pharmacodynamic studies to investigate the metabolism, distribution, and elimination of the drug in the body. The chemical formula of [13C6]-Prasugrel is C20H20ClNO3S. It contains six carbon atoms that are labeled with the stable isotope carbon-13, which allows for the drug to be tracked in biological systems using mass spectrometry. The drug is metabolized in the liver by cytochrome P450 enzymes, primarily CYP3A4 and CYP2B6, to form its active metabolite. The active metabolite has a longer half-life than the parent drug and is responsible for the antiplatelet effects. Dosage of [13C6]-Prasugrel varies depending on the study design and the specific research question being investigated. It is typically administered orally, and blood samples are collected at various time points to measure drug concentrations. The labeled version of prasugrel is a valuable tool in understanding the pharmacokinetics and pharmacodynamics of the drug, which can ultimately inform clinical practice and improve patient outcomes.